Download PDF
Pharmacopsychiatry 2003; 36(5): 197-205
DOI: 10.1055/s-2003-43050
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Dosage Finding and Outcome of Venlafaxine Treatment in Psychiatric Outpatients and Inpatients: Results of a Drug Utilization Observation Study

M. Linden1 , K. Ludewig1 , T. Munz2 , W. Dierkes2
  • 1Research Group Psychosomatic Rehabilitation, UKBF, Free University of Berlin, Germany
  • 2Medical Department, Wyeth-Pharma GmbH, Münster, Germany
Further Information

Publication History

Received: 19.7.2002 Revised: 26.9.2002

Accepted: 6.11.2002

Publication Date:
18 May 2004 (online)

Also available at
    Permissions and Reprints

Background: Venlafaxine is an antidepressive drug with the special characteristic of inhibiting both synaptic serotonin and norepinephrine reuptake. This double action is dosage dependent, with the relatively weaker inhibition of norepinephrine becoming clinically relevant only at higher dosages. This allows treatment to be tailored towards the needs of individual patients through differential dosing. It is unknown, however, how physicians use this unique feature in prescribing venlafaxine in routine treatment.

Method: Data from a drug utilization observation (DUO) study, including 6706 patients, are used to investigate which patient and setting variables predict dosage of venlafaxine as prescribed by psychiatrists in inpatient and outpatient settings. Treatment outcome and adverse drug reactions (ADR) were analyzed for different dosage groups.

Results: Treatment setting is the most important factor in predicting high (> 75 mg/day) or low (up to 75 mg/day) dosage of venlafaxine, with inpatients receiving higher dosages. Severity of illness and a history of previous treatment with major antidepressives are also related to higher dosages. Although the total rate of ADR did not increase with increased dosage, the profile of drug reactions changed. Response to therapy was better in cases of non-chronic, major depression with no treatment history of antidepressives. Additionally, increased dosage increased the likelihood of response in outpatients. In both settings, very high dosages predicted better response to venlafaxine among severely ill patients.

Conclusion: Venlafaxine at a dosage of 75 mg/day is sufficient for the majority of cases. In extremely ill patients, higher dosages are associated with additional benefits. Therefore, a stepwise dosage regimen is suggested, with an increase of dosage to upper limits in cases of non-response before discontinuation of treatment with venlafaxine.

Key words

Depression - antidepressives - venlafaxine - dosage - drug utilization observation - treatment-resistant depression - treatment algorithm

References

  • 1 Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.  J Psychiat Res. 1996;  30 441-452
    CrossrefPubMedGoogle Scholar
  • 2 Crismon M L, Trivedi M, Pigott T A, Rush A J, Hirschfeld R MA, Kahn D A, DeBattista C, Nelson J C, Nierenberg A A, Sackheim H A, Thase M E. The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.  J Clin Psychiat. 1999;  60 142-156
    PubMedGoogle Scholar
  • 3 DeMontigny C, Silverstone P, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multi-center, open-label trial.  J Clin Psychopharmacol. 1999;  19(5) 401-406
    CrossrefPubMedGoogle Scholar
  • 4 Derivan A, Entsuah R, Haskins T, Rudolph R for the Venlafaxine XR 214 Study g roup. Double-blind, placebo-/comparator controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder.  Eur Neuropsychopharmacol. 1998;  8 (suppl. 1) 26
    PubMedGoogle Scholar
  • 5 Deutsches Ä rzteblatt. Ergebnisse der Ärztestatistk.  Deutsches Ärzteblatt. 1999;  26 3-11
    PubMedGoogle Scholar
  • 6 Dierick M, Ravissa L, Realini R, Martin A. A double blind comparison of venlafaxine and flouxetine for treatment of major depression in outpatients.  Prog Neuro-Psychopharmacol Biol Psychiat. 1996;  25 57-71
    PubMedGoogle Scholar
  • 7 Dilling H, Mombour W, Schmidt M H (Hrsg.). Internationale Klassifikation psychischer Störungen (ICD-10 Kapital V) /Weltgesundheitsorganisation. 1993 Verlag Hans Huber
    Google Scholar
  • 8 Entsuah A R, Rudolph R L, Chitra R. Effectiveness of venlafaxin treatment in a broad spectrum of depressed pati.ents: A meta-analysis.  Psychopharmacol Bull. 1995;  31 759-766
    PubMedGoogle Scholar
  • 9 Guelfi J D, White C, Hackett D, Guichoux J Y, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depressive disorder and melancholia.  J Clin Psychiat. 1995;  56 450-458
    PubMedGoogle Scholar
  • 10 Harvey A T, Rudolph R L, Preskorn S H. Evidence of the dual mechanisms of action of venlafaxine.  Arch Gen Psychiat. 2000;  57 503-509
    CrossrefPubMedGoogle Scholar
  • 11 Haskins J T, Rudolph R, Pallay A. Derivan A for the Venlafaxine XR 210 Study group double-blind, placebo-controlled study of once daily venlafaxine. XR in outpatients with generalized anxiety disorder (GAD). Eur Neuropsychopharmacol 1998 8(Suppl 1): 26
    Google Scholar
  • 12 Hellerstein D, Batchelder S, Little S, Fedak M, Kreditor D, Rosenthal J. Venlafaxine in the treatment of dysthymia: an open-label study.  J Clin Psychiat. 1999;  60 845-849
    PubMedGoogle Scholar
  • 13 Hyfte van D MH, Vries Robbe de P F, Tjandra-Maga T B, Maas van der A AF, Zitman F G. Towards a more rational use of psychoactive substances in clinicl practice.  Pharmacopsychiatry. 2001;  34 13-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kahn A, Fabre L, Rudolph R. Venlafaxine in depressed outpatients.  Psychopharmacol Bull. 1991;  27 141-144
    PubMedGoogle Scholar
  • 15 Kahn A, Upton V, Rudolph R, Entsuah R, Leventer S, for the Venlafaxine Investigator Study G roup. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study.  J Clin Psychopharmacol. 1998;  18 19-25
    CrossrefPubMedGoogle Scholar
  • 16 Kelsey J E. Dose-response relationship with venlafaxine.  J Clin Psychopharmacol. 1996;  16 21-26
    PubMedGoogle Scholar
  • 17 Laux G: Cost-benefit analysis of newer versus older a ntidpressants. Pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressant.  Pharmacopsychiatry. 2001;  34 1-5
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Linden M. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process.  Psychopharmacol Bull. 1993;  29 51-56
    PubMedGoogle Scholar
  • 19 Linden M. Phase IV research and drug utilization observation studies.  Pharmacopsychiatry. 1997;  30 1-3
    PubMedGoogle Scholar
  • 20 Linden M. Theory and practice in the management of depressive disorders.  Int Clin Psychopharmacol. 1999;  14 15-25
    PubMedGoogle Scholar
  • 21 Linden M, Ludewig K, Munz T. Depressive Erkrankungen und antidepressive Therapie. Ein Vergleich von Nervenarztpraxis und psychiatrischer Klinik.  Nervenarzt. 2001;  72 521-528
    CrossrefPubMedGoogle Scholar
  • 22 Mendels J, Johnston R, Mattes J, Riesenberg R, Efficacy and safety of b .i.d. doses of venlafaxine in a dose-response study.  Psychopharmacol Bull. 1993;  29 169-174
    PubMedGoogle Scholar
  • 23 Muth E A, Haskins J T, Moyer J A,. et al . Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030. An ethyl cyclohexanol derivative.  Biochem Pharmacol. 1986;  35 493-4497
    CrossrefPubMedGoogle Scholar
  • 24 National Institute of Mental Health. Clinical Global Impressions. In: Guy W, Bonato RR (eds) Manual for the ECDEU Assessment Battery. Chevy Chase MD 1976: 12 - 1-12 - 6
    Google Scholar
  • 25 Nierenberg A A, Feighner J P, Rudolph R, Cole J O, Sullivan J. Venlafaxine for Treatment-resistant unipolar depression.  J Clin Psychopharmacol. 1994;  14 419-423
    PubMedGoogle Scholar
  • 26 Nutt D, Johnson F N. Potential applications of venlafaxine.  Rev Contemp Pharmacother. 1998;  9 G33-44
    PubMedGoogle Scholar
  • 27 Pollack M H, Worthington J J, Otto M W. et al . Double-blind, placebo-controlled trial of venlafaxine for panic disorder.  Psychopharmacol Bull. 1996;  32 496
    PubMedGoogle Scholar
  • 28 Rauch S L, O’Sullivan R L, Jenike M A. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases.  J Clin Psychopharmacol. 1996;  16 81 - 84
    CrossrefPubMedGoogle Scholar
  • 29 Rudolph R L, Fabre L F, Feigner J P, Rickels K, Entsuah R, Derivan A T. Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.  J Clin Psychiat. 1998;  59 116-122
    PubMedGoogle Scholar
  • 30 Rudolph R L, Derivan A T. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.  J Clin Psychopharmacol. 1996;  16(suppl. 1) 54-59
    PubMedGoogle Scholar
  • 31 Schaaf B, Linden M, Weber H J. An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization observation study on fluoxetine.  Pharmacopsychiatry. 1997;  30 44-51
    PubMedGoogle Scholar
  • 32 Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression.  J Clin Psychopharmacol. 1991;  11 233-236
    PubMedGoogle Scholar
  • 33 Sheehan D. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.  J Clin Psychiat. 1999;  60 (supp. 22) 23-28
    PubMedGoogle Scholar
  • 34 Sinclair J, Britwistle J, Baldwin D. Verträglichkeit von Venlafaxin.  Rev Contemp Pharmacother. 1998;  9 G45-57
    PubMedGoogle Scholar
  • 35 Stahl S. Are two antidepressant mechanisms better than one?.  J Clin Psychiat. 1997;  58(8) 339-340
    PubMedGoogle Scholar
  • 36 Wyeth Pharma GmbH, Germany, product information for Trevilor. November 1998
    Google Scholar
  • 37 Zinardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.  J Clin Psychiat. 2000;  61 26-29
    PubMedGoogle Scholar
  • 38 Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhbitors.  Pharmacopsychiatry. 2001;  34 119-127
    Article in Thieme ConnectPubMedGoogle Scholar

Prof. Dr. M. Linden

Dept. of Behavioral Medicine

BfA-Klinik Seehof

Lichterfelder Allee 55

14513 Teltow/Berlin, Germany

Phone: 0049 (+3328) 345678

Fax: 0049 (+3328) 345555

Email: linden@zedat.fu-berlin.de